Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

GastroEsophageal Cancer × Lapatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 156 Neoplasms 30 Neoplasm Metastasis 26 Breast Neoplasms, Male 15 Brain Neoplasms 14 Stomach Neoplasms 7 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Urinary Bladder Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Inflammatory Breast Neoplasms 5 Prostatic Neoplasms 4 Glioblastoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Carcinoma, Non-Small-Cell Lung 4 Pancreatic Neoplasms 3 Gliosarcoma 3 Ependymoma 3 Carcinoma, Squamous Cell 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumors 2 Salivary Gland Neoplasms 2 Recurrence 2 Osteitis Deformans 2 Oligodendroglioma 2 Neuroma, Acoustic 2 Neurofibromatosis 2 2 Lung Neoplasms 2

Interventions

Surveys and Questionnaires 2 Lapatinib 1 Immune Checkpoint Inhibitors 1 Exercise 1 Diet Therapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01145404 2014-07-02

GastroLap

National Center for Tumor Diseases, Heidelberg

Phase 2 Terminated

Gastrointestinal

GastroEsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡